

Newsletter week 33, 2019

Dear STATICH collaborators,


August 13th, 2019

Trial status

20 participants have so far been included into STATICH: 8 in the antiplatelets part and 12 in the anticoagulants part.

Five-year risk of major ischaemic and haemorrhagic events after ICH

In a recent cohort of 310 ICH patients, the risk of subsequent ischaemic events largely surpassed the risk of new haemorrhagic events. The cumulative risk of ischaemic events was 5.9% at 1 year and 15.2% at 5 years, and the risk of haemorrhagic events was 4.9% at 1 year and 6.2% at 5 years. Interestingly, patients with deep ICH had a risk of ischaemic events that was 6 times higher than the risk of haemorrhagic events at 5 years (Stroke. 2019 May;50(5):1100-1107):



These observational data cannot guide antithrombotic treatment decisions after ICH, but emphasise the need to identify the subgroups of patients with different ICH locations in STATICH. It is therefore important that we receive CT and MRI scans on all patients included into the trial.

Reminder: STATICH collaborators' meeting at the Nordic Stroke Congress 2019 in Tromsø

Time: **Thursday August 22nd at 12.15-13.15**

Place: **You will find information about the meeting room on information screens on arrival.**

Coffee/tea will be served, and please bring your lunch. We hope to see you there! If you will be able to join, please reply to k.t.larsen@medisin.uio.no.

Poster presentation at the Nordic Stroke Congress

STATICH will also have a poster at the Nordic Stroke Congress in Tromsø and you are welcome to come by for discussions.

Thank you for participating and remember to keep patients in mind for STATICH!

Best wishes,

Kristin T. Larsen
Oslo

Johanna Pennlert
Umeå

Eva-Lotta Glader
Umeå

Christina Kruuse
Copenhagen

Eivind Berge
Oslo